Climb Bio, Inc.

Stage 3 · Topping · week 3

As of Oct 22, 2026, Climb Bio is in Stage 3, the topping phase, now in week 3 (since Oct 6, 2026). It closed at $10.54, 40.9% below its 52-week high and above its 200-day average, which is rising.

Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. More about the company

$10.54

-3.04% today

$605M · Small cap

Market Neutral — Building

Pro read

Pro

Our read

Topping: the uptrend is tiring

Setup score

—

Momentum

Steady

Edge

—

Is CLYM early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 19w

S2 17w

S4 33w

S2 42w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 19w → S1 7w → S2 6w → S3 1w → S2 17w → S3 7w → S2 1w → S3 6w → S4 33w → S1 10w → S2 10w → S3 5w → S2 42w → S3 2w current

Total tracked: 165 weeks across 14 stage runs.

CLYM among Biotechnology8th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%

vs 52W High

-40.9%

$1.64 lo$17.84 hi

40.9% below 52W high, weakening from peak

The stock is rolling over from its 52-week high. In Stage 3 distribution, new long positions carry high risk.

Stage Maturity

Week 3

1w13w26w

Week 3, early distribution

How long this stock has been in Stage 3 distribution. Longer tops often precede deeper Stage 4 declines.

vs 200 DMA

3.2%

200 DMA: $10.22 · rising

Stock is losing its 200 DMA. Once lost, it confirms Stage 4 risk. This is a major red flag for existing holders.

Rel Volume

0.45x

vs 50-day avg

Volume spikes on down days during Stage 3 signal distribution, with institutions exiting. Stage analysis reads that as a warning against new long positions.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-15.8%

-17.9%

+16.9%

YTD

+181.1%

+366.4%

Scan Membership

Breakout Watch

Latest: 2024-09-23

5 appearances in last 60 days. First seen: 2023-02-13.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S3

Wk 3 · Vol 0.45x

2026-10-21S3

Wk 3 · Vol 0.53x

2026-10-20S3

Wk 3 · Vol 0.95x

2026-10-19S3

Wk 2 · Vol 0.85x

2026-10-16S3

Wk 2 · Vol 0.69x

2026-10-15S3

Wk 2 · Vol 0.36x

2026-10-14S3

Wk 2 · Vol 0.68x

2026-10-13S3

Wk 2 · Vol 0.62x

2026-10-12S3

Wk 1 · Vol 0.63x

2026-10-09S3

Wk 1 · Vol 0.43x

2026-10-08S3

Wk 1 · Vol 0.78x

2026-10-07S3

Wk 1 · Vol 0.52x

Moving averages & range

50 DMA

$13.42

200 DMA

$10.22

52W High

$17.84

52W Low

$1.64

5D Low

$9.73

Resistance levels (recent highs)

20d High

$11.74

60d High

$17.84

120d High

$17.84

250d High

$17.84

Next resistance

+11.4%

to 20d High

ROE

-27.1%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 2.5

Climb Bio: quick answers

What stage is Climb Bio in?

As of Oct 22, 2026, Climb Bio (CLYM) is in Stage 3, the topping phase. It entered Stage 3 on Oct 6, 2026 and is in week 3. What the four stages mean

Is Climb Bio in an uptrend?

Its uptrend has stalled. Climb Bio is in Stage 3, the topping phase that follows an advance. It trades 3.2% above its 200-day average, which is rising.

How far is Climb Bio from its 52-week high?

Climb Bio closed at $10.54 on Oct 22, 2026, 40.9% below its 52-week high of $17.84. Its 52-week low is $1.64.

How has Climb Bio performed over the past year?

As of Oct 22, 2026, Climb Bio is up 366.4% over the past year and up 181.1% so far in 2026.

Which sector and industry is Climb Bio in?

Climb Bio is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug which is in phase 2 clinical trials for the treatment of primary membranous nephropathy and immune thrombocytopenia; and Phase 1b clinical trial indicated for the systemic lupus erythematosus. In addition, the company is developing CLYM116, a preclinical stage anti A Proliferation-inducing Ligand (APRIL) monoclonal antibody for the treatment of immunoglobin A nephropathy (IgAN) and other B-cell mediated diseases. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wellesley Hills, Massachusetts.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.